Outlook Therapeutics, Inc. - Common Stock (OTLK)

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:OTLK),(NASDAQ:EYEN),(NYSE:BLCO),(NASDAQ:BMEA) EQNX::TICKER_END

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASDAQ: OTLK) on behalf of long-term stockholders following a class action complaint that was filed against Outlook on November 3, 2023 with a Class Period from December 29, 2022 to August 29, 2023. Our investigation concerns whether the board of directors of Outlook have breached their fiduciary duties to the company.

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus cameras are sophisticated instruments utilized in ophthalmology for capturing detailed images of the retina. They employ a specialized optical design akin to an indirect ophthalmoscope, with the angle of view being a key parameter defining their functionality… Fundus photography enables physicians to meticulously examine retinal changes over time, facilitating collaboration among colleagues and enhancing patient care. A recent report from Precedence Research said: “The fundus cameras market experiences growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). Traditionally, fundus photography with film-based cameras, preferably through pharmacologically dilated pupils, has been pivotal in documenting AMD severity. The emergence of high-resolution digital cameras presents new opportunities in the market. Comparisons among different imaging systems, including nonstereoscopic color retinal images taken with digital cameras through dark-adapted and dilated pupils, as well as stereoscopic images captured with standard film cameras, highlight the expanding applications of fundus cameras. Such comparisons underscore the need for versatile imaging solutions to accommodate diverse clinical scenarios, thus fueling the growth in the fundus cameras market.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Outlook Therapeutics, Inc. (NASDAQ: OTLK), Eyenovia, Inc. (NASDAQ: EYEN), Bausch + Lomb Corporation (NYSE: BLCO), Biomea Fusion, Inc. (NASDAQ: BMEA).

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally

Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target. 

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Dec. 31, 2023 (GLOBE NEWSWIRE) --

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between August 3, 2021 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) securities between August 3, 2021 and August 29, 2023, inclusive (the “Class Period”).

If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK.

NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Dec. 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between August 3, 2021 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) --

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

If you suffered losses exceeding $50,000 investing in Outlook securities between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.